| Phase I Nov. 12, 02 to Nov. 11, 03 (365 days) | Phase II Nov. 12, 03 to Mar. 11, 04 (120 days) |
---|---|---|
No. of patients | 100 | 100 |
No. of treatment courses | 100 | 100 |
Age (yr), median (range) | 57 (17–93) | 63 (16–91) |
Gender, N | Â | Â |
   Male | 45 | 50 |
SCr1 (μmol/L), median (range) | 84 (40–541) | 89 (35–641) |
Length of Stay (d), mean (range) | 12 (1–84) | 17 (1–165) |
Service Area, N | Â | Â |
   General Surgery | 31 | 30 |
   Medicine | 22 | 11 |
   Emergency | 15 | 11 |
   Intensive Care Unit | 7 | 8 |
   Urology | 3 | 12 |
   Other | 222 | 283 |
Indication, N | Â | Â |
   Off-label indications4 | 38 | 35 |
   Intra-abdominal infection | 18 | 15 |
   Respiratory tract infection | 15 | 16 |
   Urinary tract infection | 15 | 15 |
   Other | 145 | 196 |